Alaunos Therapeutics
Aldesleukin (IL-2)(Alaunos Therapeutics)은 Gynecologic Cancer 표적 치료제로, Gynecologic Cancer; Colorectal Cancer 영역에서 개발·상용화 중입니다. 작용기전: targeted therapeutic approach to treating OA by blocking the iNOS-TXNIP-NLRP3 signaling. Phase 2에서 효능·안전성 신호를 검증 중입니다. 대표 임상 효능: ORR 59% (ClinicalTrials.gov NCT03729245). 차별점: unique cytotoxic program was marked by elevated Granzyme-K (GzmK) and Thrombospondin-4 (Tsp-4), a thrombospondin family extrac.
Gynecologic Cancer
Gynecologic Cancer; Colorectal Cancer
Discontinued
bispecific antibody-engaged Vγ9Vδ2-T cell effector functio
may
LNP Vaccination Drives Therapeutic Efficacy in Preclinical Models for Autoimmunity
humanized PD1 + / + mice
unique cytotoxic program was marked by elevated Granzyme-K (GzmK) and Thrombospondin-4 (Tsp-4), a thrombospondin family extrac
targeted therapeutic approach to treating OA by blocking the iNOS-TXNIP-NLRP3 signaling
T cell antitumor activity and was found to substantially enhance CD1d-Vδ2 bsTCE-induced Vγ9Vδ2-T cell activation
apoptosis
PD-1, TIM-3, LAG-3) was analyzed by flow
resistance to experimental A
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Alaunos Therapeutics
Aldesleukin (IL-2)(Alaunos Therapeutics)은 Gynecologic Cancer 표적 치료제로, Gynecologic Cancer; Colorectal Cancer 영역에서 개발·상용화 중입니다. 작용기전: targeted therapeutic approach to treating OA by blocking the iNOS-TXNIP-NLRP3 signaling. Phase 2에서 효능·안전성 신호를 검증 중입니다. 대표 임상 효능: ORR 59% (ClinicalTrials.gov NCT03729245). 차별점: unique cytotoxic program was marked by elevated Granzyme-K (GzmK) and Thrombospondin-4 (Tsp-4), a thrombospondin family extrac.
Gynecologic Cancer
Gynecologic Cancer; Colorectal Cancer
Discontinued
bispecific antibody-engaged Vγ9Vδ2-T cell effector functio
may
LNP Vaccination Drives Therapeutic Efficacy in Preclinical Models for Autoimmunity
humanized PD1 + / + mice
unique cytotoxic program was marked by elevated Granzyme-K (GzmK) and Thrombospondin-4 (Tsp-4), a thrombospondin family extrac
targeted therapeutic approach to treating OA by blocking the iNOS-TXNIP-NLRP3 signaling
T cell antitumor activity and was found to substantially enhance CD1d-Vδ2 bsTCE-induced Vγ9Vδ2-T cell activation
apoptosis
PD-1, TIM-3, LAG-3) was analyzed by flow
resistance to experimental A
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.